Cargando…
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
BACKGROUND: The detection of V600E BRAF mutations has fundamental clinical consequences as the treatment option with BRAF inhibitors such as vemurafenib or dabrafenib yields response rates of ∼48%. Heterogeneity with respect to BRAF mutation in different metastases has been described in single cases...
Autores principales: | Heinzerling, L, Baiter, M, Kühnapfel, S, Schuler, G, Keikavoussi, P, Agaimy, A, Kiesewetter, F, Hartmann, A, Schneider-Stock, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844905/ https://www.ncbi.nlm.nih.gov/pubmed/24196789 http://dx.doi.org/10.1038/bjc.2013.622 |
Ejemplares similares
-
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
por: Heinzerling, L, et al.
Publicado: (2013) -
Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Heinzerling, L, et al.
Publicado: (2014) -
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
por: Lin, J, et al.
Publicado: (2011) -
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012) -
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)